Literature DB >> 34861377

Clinical characteristics limiting the durability of humoral response to BNT162b2 in patients with solid cancer.

V Di Noia1, F Pimpinelli2, D Renna3, V Barberi4, R Pellini5, A Morrone6, D Giannarelli7, F Cognetti8.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34861377     DOI： 10.1016/j.annonc.2021.11.015

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  2 in total

1.  Potentiation of humoral response to the BNT162b2 vaccine after the third dose in patients with solid cancer.

Authors:  V Di Noia; F Pimpinelli; D Renna; M T Maccallini; L Gariazzo; F Riva; E Sperandio; D Giannarelli; F Cognetti
Journal:  Ann Oncol       Date:  2022-02-22       Impact factor: 51.769

2.  Immunogenicity of BNT162b2 mRNA-Based Vaccine against SARS-CoV-2 in People with Cystic Fibrosis According to Disease Characteristics and Maintenance Therapies.

Authors:  Gianfranco Alicandro; Valeria Daccò; Lisa Cariani; Chiara Rosazza; Calogero Sathya Sciarrabba; Federica Ferraro; Chiara Lanfranchi; Paola Medino; Daniela Girelli; Carla Colombo
Journal:  Biomedicines       Date:  2022-08-17
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.